ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Individuals with Alzheimer's disease and low tau burden: Characteristics and implications.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- Are the factors associated with cognitive performance generalizable across cohorts?NeuroImage. Clinical · 2026Article
- The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.Alzheimer's research & therapy · 2026Article
- Hierarchical organization of tau topography across the Alzheimer's disease continuum integrates amyloid, connectome, and intrinsic molecular vulnerability.Communications biology · 2026Article
- Biological classification of memory clinic patients.Brain : a journal of neurology · 2026Article
- Brain network dynamics determine tau presence while regional vulnerability governs tau load in Alzheimer's disease.Research square · 2026Article
- Alzheimer's Disease Pathologies Affect Dopaminergic Neural Mechanisms of Memory.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer's disease.medRxiv : the preprint server for health sciences · 2026Article
- Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.Nature neuroscience · 2025Article
- Factors associated with age at tau pathology onset and time from tau onset to dementia in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.JAMA · 2025Observational
- Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer's and Lewy body disease.Brain : a journal of neurology · 2025Article
- Characterizing visual read tau-PET-negative participants with Alzheimer's disease dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases; proof of concept in the ADNI study.Molecular psychiatry · 2025Article
- Establishing tau-PET cut-points for cognitive diagnosis withImaging neuroscience (Cambridge, Mass.) · 2025Article
- Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- The Taiwan-ADNI workflow toward integrating plasma p-tau217 into prediction models for the risk of Alzheimer's disease and tau burden.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Self- and study partner-reported cognitive decline in older adults without dementia: The role of α-synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Pilot implementation of the revised criteria for staging of Alzheimer's disease by the Alzheimer's Association Workgroup in a tertiary memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease.Molecular neurodegeneration · 2024Observational
- The ADNI PET Core at 20.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
introductionAbnormal amyloid-beta (Aβ) and tau deposition define Alzheimer's Disease (AD), but non-elevated tau is relatively frequent in patients on the AD pathway.
methodsWe examined characteristics and regional patterns of 397 Aβ+ unimpaired and impaired individuals with low tau (A+T-) in relation to their higher tau counterparts (A+T+).
resultsSeventy-one percent of Aβ+ unimpaired and 42% of impaired Aβ+ individuals were categorized as A+T- based on global tau. In impaired individuals only, A+T- status was associated with older age, male sex, and greater cardiovascular risk. α-synuclein was linked to poorer cognition, particularly when tau was low. Tau burden was most frequently elevated in a common set of temporal regions regardless of T+/T- status. DISCUSSION: Low tau is relatively common in patients on the AD pathway and is linked to comorbidities that contribute to impairment. These findings have implications for the selection of individuals for Aβ- and tau-modifying therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.